Provided by Tiger Fintech (Singapore) Pte. Ltd.

Immunic, Inc.

1.15
+0.03002.68%
Post-market: 1.13-0.0200-1.74%17:13 EDT
Volume:534.22K
Turnover:608.67K
Market Cap:103.59M
PE:-1.02
High:1.17
Open:1.12
Low:1.10
Close:1.12
Loading ...

Company Profile

Company Name:
Immunic, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
85
Office Location:
1200 Avenue of the Americas,Suite 200,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Directors

Name
Position
Daniel Vitt
Director, Chief Executive Officer, President
Duane Nash
Executive Chairman of the Board
Barclay Phillips
Lead Independent Director
Jörg Neermann
Director
Maria Törnsén
Director
Richard Rudick
Director
Tamar Howson
Director

Shareholders

Name
Position
Daniel Vitt
Director, Chief Executive Officer, President
Glenn Whaley
Chief Financial Officer
Andreas Muehler
Chief Medical Officer
Duane Nash
Executive Chairman of the Board
Hella Kohlhof
Chief Scientific Officer
Inderpal Singh
General Counsel
Patrick Walsh
Chief Business Officer